Home > Press > Picosun tops previous 12 month sales record in six months
Picosun Board of Directors, from left: Prof., Ph.D Tech. Lauri Niinistö, one of the key persons in developing Atomic Layer Deposition processes and applications in Academia since late 1970s; (Left front row) Ph.D. Tech. Tuomo Suntola, the inventor of ALD method; Picosun President and CEO, M. Econ. Kustaa Poutiainen; Picosun CTO, Mr. Sven Lindfors, designer of ALD systems since 1975; Prof., Ph.D Jorma Routti, one of the founders of Finnish venture capital and one of Europe's leading technology experts; former Director General of the Research Directorate of the European Union. Furthest right: Picosun Managing Director, M. Sc. Juhana Kostamo. |
Abstract:
"Picosun has sailed through the perils of the global downturn with amazing speed," says Kustaa Poutiainen, President and CEO of Picosun. "We have maintained profitability all through this turmoil, nailed new Q 1 sales record for May - July 2009 and now top our previous annual 12 month sales record in just six months time."
"Picosun combines the superior design of its ALD systems with the unparallel experience of its people. Our ancestry in ALD is beyond comparison," he says.
The man who invented and patented the method of ALD (at the time, the method was called ALE, short for Atomic Layer Epitaxy) back in 1975, Dr. Tuomo Suntola, continues to serve as a member of the board of directors of Picosun. Combined, Picosun people possess well over 200 years of first-hand ALD experience and have been instrumental in producing over 100 patents on the science and technique of ALD over a period of well over 30 years.
"Sales records as such are not important. The importance comes from the fact that more and more customers are buying into the exclusive club of Picosun Partners verifying the image of Picosun as a leading ALD actor with the best systems solutions on offer," Poutiainen says.
Picosun has been extremely strong in Europe during and after the summer period. "This is very significant, because the slowing down of the markets for thin film systems has been felt at the markets where we have traditionally been very strong: North America and Asia. During the past couple of weeks we have seen first signs which may indicate that the American and Asian markets are bouncing back. Once this happens, Picosun will need every ounce of afterburner effect it can muster: we will surely fly higher than ever before," Poutiainen predicts.
####
About Picosun Oy
Picosun develops and manufactures Atomic Layer Deposition (ALD) reactors for micro- and nanotechnology applications. Picosun represents continuity to over three decades of ALD reactor manufacturing in Finland. Picosun is based in Espoo, Finland with production, R&D and laboratory facilities in Kirkkonummi, Finland and has its US headquarters in Detroit, Michigan. SUNALE™ ALD process tools are installed in various universities, research institutes and companies across Europe, USA and Asia. Picosun Oy is a part of Stephen Industries Inc Oy.
For more information, please click here
Contacts:
Picosun Oy, Mr. Juhana Kostamo, Managing Director Tietotie 3, FI-02150 Espoo, Finland
Tel. +358 50 321 1955
Fax. +358 20 722 7012
Copyright © Picosun Oy
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||